191 – 200 of 363
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer
2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(15 Suppl). p.5044-5044(
- Contribution to journal › Published meeting abstract
-
Mark
Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
2015) American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium In Journal of Clinical Oncology 33(7 Suppl). p.288-288(
- Contribution to journal › Published meeting abstract
- 2014
-
Mark
Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy.
(
- Contribution to journal › Article
-
Mark
Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study.
(
- Contribution to journal › Article
-
Mark
TCF7L2 type 2 diabetes risk variant, lifestyle factors, and incidence of prostate cancer.
(
- Contribution to journal › Article
-
Mark
Identification of plasma protein profiles associated with risk groups of prostate cancer patients.
(
- Contribution to journal › Article
-
Mark
REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer.
(
- Contribution to journal › Article
-
Mark
Androgen receptor polymorphism dependent variation in prostate specific antigen concentrations of European men.
(
- Contribution to journal › Article
-
Mark
Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens.
(
- Contribution to journal › Article
-
Mark
Galiellalactone is a Direct Inhibitor of STAT3 in Prostate Cancer Cells.
(
- Contribution to journal › Article